[Percutaneous treatment of acute pulmonary embolism: state of the art]

G Ital Cardiol (Rome). 2022 Jul;23(7 Suppl 2):13S-21S. doi: 10.1714/3838.38223.
[Article in Italian]

Abstract

Acute pulmonary embolism (PE) is a common disease associated with high mortality rates that vary widely according to patient clinical presentation and hemodynamic status. According to international guidelines, systemic thrombolysis (ST) is the mainstem treatment in patients with high risk PE and intermediate-high risk PE evolving towards hemodynamic decompensation, showing lower mortality compared with anticoagulant therapy alone despite a high rate of bleeding events. Considering that a large proportion of patients presents contraindication to ST, catheter-directed therapies (CDTs) could tackle some unsolved issues, targeting the treatment to the pulmonary arteries, avoiding the dreaded complications of ST.The aim of this review is to describe the current indication for CDTs in terms of patient selection and timing of treatment, to describe contemporary available medical devices and techniques, discussing current knowledge of safety and efficacy and the importance of multidisciplinary team in PE management.

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Fibrinolytic Agents
  • Humans
  • Pulmonary Embolism* / drug therapy
  • Risk Factors
  • Thrombolytic Therapy* / methods
  • Treatment Outcome

Substances

  • Fibrinolytic Agents